SCHEMBL17295572

SCHEMBL17295572

O=C1C(=Cc2ccc3[nH]ccc3c2)SC(=Nc2ccccc2)N1Cc1ccco1

nearest known ligand 0.64

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ FAAH O00519 2/20 0.64
▸ MEN1 O00255 1/20 0.58
▸ LMNA P02545 1/20 0.58
▸ FNTA P49354 1/20 0.58
▸ FNTB P49356 1/20 0.58
▸ KMT2A Q03164 1/20 0.58
▸ SMN1; SMN2 Q16637 1/20 0.58
▸ NPSR1 Q6W5P4 1/20 0.58
▸ PTPN1 P18031 6/20 0.51
▸ ACP1 P24666 6/20 0.51
▸ CA9 Q16790 10/20 0.48
▸ CA2 P00918 1/20 0.48
▸ PTPN2 P17706 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17295570 1.00 FAAH (0.64) FAAHMEN1LMNAFNTAFNTB
SCHEMBL17302227 0.87 PTPN1 (0.64) PTPN1ACP1CA9CA2PTPN2
SCHEMBL17295388 0.84 FAAH (0.62) FAAHMEN1LMNAFNTAFNTB
SCHEMBL17302192 0.84 FAAH (0.62) FAAHMEN1LMNAFNTAFNTB
SCHEMBL17302245 0.84 FAAH (0.76) FAAHMEN1LMNAFNTAFNTB
SCHEMBL17295376 0.84 FAAH (0.76) FAAHMEN1LMNAFNTAFNTB
SCHEMBL17309449 0.81 FAAH (0.76) FAAHMEN1LMNAFNTAFNTB
SCHEMBL22386375 0.81 FAAH (0.73) FAAHMEN1LMNAFNTAFNTB
SCHEMBL19481515 0.81 FAAH (0.76) FAAHMEN1LMNAFNTAFNTB
SCHEMBL17302191 0.81 FAAH (0.57) FAAHMEN1LMNAKMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3148990-A1 THIAZOLIDINONE COMPOUNDS AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL DISORDERS AND INFLAMMATION, IN PARTICULAR NEUROINFLAMMATION Universität Bern (CH) 2017-04-05 — — EP disclosed
WO-2015181337-A1 THIAZOLIDINONE COMPOUNDS AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL DISORDERS AND INFLAMMATION, IN PARTICULAR NEUROINFLAMMATION Universität Bern (CH) 2015-12-03 — — WO disclosed
Send feedback